Artificial intelligence is rapidly reshaping how clinical trials are designed, managed and executed worldwide, and Vietnam is beginning to benefit from this transformation as the country strengthens its position as an emerging destination for pharmaceutical research.
Although no standalone valuation has been published for Vietnam's AI in Clinical Trials Market, industry analysis estimates the sector is currently worth US$2.5–4.0 million in 2025 and could expand to US$12–18 million by 2030.
AI is increasingly being deployed throughout the clinical trial lifecycle, helping pharmaceutical companies, biotechnology firms and contract research organisations (CROs) improve efficiency while reducing both cost and development timelines. Machine learning algorithms can identify suitable patients more quickly, optimise trial protocols, predict recruitment challenges, detect safety signals and automate large volumes of clinical documentation.
The market includes technologies such as:
- AI-powered patient recruitment
- Clinical trial participant matching
- Protocol design optimisation
- Predictive analytics
- Electronic data capture (EDC)
- AI-assisted medical imaging analysis
- Natural language processing for clinical documents
- Risk-based monitoring
- Digital biomarkers
- Generative AI for trial operations
Several structural trends are supporting rapid market growth across Vietnam:
- Expansion of pharmaceutical and biotechnology research.
- Rising adoption of digital health technologies.
- Increasing clinical trial activity across Asia.
- Growing investment in precision medicine.
- Government support for AI and healthcare digitalisation.
- Greater availability of electronic medical records.
- Increasing collaboration between hospitals, universities and global pharmaceutical companies.
Vietnam's clinical research infrastructure continues to strengthen. According to IMARC Group, the country's Clinical Trial Management Systems (CTMS) Market reached US$5.4 million in 2025 and is forecast to grow to US$10.1 million by 2034. The report identifies the integration of artificial intelligence, machine learning and advanced analytics as key drivers of the next generation of clinical trial management platforms.
The country's wider healthcare AI sector is expanding even more rapidly. IMARC Group estimates Vietnam's Artificial Intelligence in Healthcare Market reached US$1.78 million in 2025 and is projected to reach US$22.48 million by 2034. Among the applications identified is clinical trial participant identification, where AI helps researchers identify eligible patients more accurately and efficiently from electronic health records and clinical datasets.
Artificial intelligence is also transforming pharmaceutical R&D. According to IMARC Group, Vietnam's AI in Drug Discovery Market reached US$9.6 million in 2025 and is forecast to reach US$94.4 million by 2034. The report highlights AI's ability to improve protocol design, patient stratification, recruitment and predictive modelling, significantly reducing clinical development costs while shortening time-to-market for new therapies.
Globally, AI in clinical trials is experiencing exceptional growth. Fortune Business Insights estimates the Global AI in Clinical Trials Market reached US$3.8 billion in 2025 and is expected to grow to US$77.3 billion by 2034. The fastest-growing applications include patient recruitment, protocol optimisation, predictive analytics and automated clinical data management, as pharmaceutical companies increasingly seek faster and more efficient trial execution.
Recent research continues to demonstrate how AI is transforming clinical development. Multi-modal AI datasets are enabling predictive models that forecast trial duration, patient dropout, adverse events and study success before recruitment begins. At the same time, researchers are exploring hybrid human-AI workflows that combine clinical expertise with generative AI to improve trial design and operational decision-making.
Vietnam's broader AI ecosystem is also gaining momentum. International investment in AI infrastructure—including new AI research and development initiatives and healthcare technology collaborations—is strengthening the country's digital capabilities and creating favourable conditions for advanced clinical research.
Leading companies developing AI solutions for clinical trials include IQVIA, Medidata (Dassault Systèmes), Oracle Health, Veeva Systems, Tempus AI, Saama, Unlearn, Deep 6 AI, Parexel, ICON plc, Medable and Clario, all of which are investing heavily in AI-enabled platforms for trial design, patient recruitment, operational efficiency and data analytics.
As Vietnam continues to expand its pharmaceutical research capabilities and embrace artificial intelligence across healthcare, AI-enabled clinical trials are expected to become a strategic competitive advantage. For pharmaceutical companies, CROs, clinical technology providers and AI software developers, Vietnam represents one of Southeast Asia's most promising emerging markets for digitally enabled clinical research.